Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
NCT ID: NCT04264260
Last Updated: 2025-09-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
42 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-12-24
Study Completion Date
2025-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This trial is to evaluate the palliative effects of colchicine on primary hepatic malignancy using the Department of Health R.O.C. approved doses and methods of administration. Colchicine will be started from 2 tablets after meal twice per day (total 2 mg), adjust the dose ranging from total minimum 1.5 mg to maximum 3 mg per day based on the condition and tolerance of the participant. One cycle of treatment is defined as 4 days treatment and 3 days off. The participants will receive repeated treatment cycles till the participants quit the trial. The control group will be originated from review of (1) patients treated by members of this research team with the same condition as the trial selected participants but not included in the trial, (2) patients with same condition as the trial selected participants reported in the literatures. The primary objective is to evaluate the palliative effects of colchicine on primary hepatic malignancy unable to receive curative treatment. The primary end point is survival of the participant. The Secondary objective is to evaluate the safety of patients treated by colchicine and the secondary end point is the side effects of colchicine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma
NCT01935700
Hepatocellular Carcinoma
Metastasis
Invasion
COMPLETED
PHASE2
A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
NCT05281926
Hepatocellular Carcinoma
UNKNOWN
PHASE1
Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma
NCT04527679
Cholangiocarcinoma, Intrahepatic
UNKNOWN
PHASE2
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
NCT01525069
Cholangiocarcinoma
Liver Neoplasms
TERMINATED
PHASE1
Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma
NCT04361331
Cholangiocarcinoma, Intrahepatic
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study procedures
1. Written informed consent before study specific procedures are undertaken. The investigators will explain the contents of the trial especially the information about the possible side effects, other alternative treatment and the right to withdraw based on the participant own willing to the candidates. Patient can choose to sign or not to sign the inform consent based on his/her own decision after completely understanding the investigators explanation.
2. The process of the experiment
Start to receive colchicine:
Participant will start to receive colchicine starting from 2 tablets after meal twice per day (total 2 mg).
Adjustment the dosage of colchicine during study: based on the following steps:
2 tablets-2 tablets-2 tablets (three times per day, after meal, total 3 mg, maximum dose)\<-\> 2 tablets -1 tablet -2 tablets (three times per day, after meal, total 2.5 mg)\<-\>2 tablets -2 tablets (twice per day, after meal, 2 mg, starting dose)\<-\>1 tablet -1 tablet -1 tablet (three times per day, after meal, 1.5 mg, minimum dose)
1. The colchicine dosage will be changed when the hepatic reserved function of the participant changes to Child score 8-9 points according to the following rules.
1. 1 tablet after meal three times per day with total dose of 1.5 mg; continue 4 days and stop for 3 days (1 cycle)
2. If the hepatic reserved function of the participant returns to Child score \< 8 points, the dosage changes to starting dose.
3. If the hepatic reserved function of the participant changes to Child score \> 9 points, colchicine will be stopped and participant receives regular follow-up only.
2. If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again according to the above steps of dose adjustment.
3. If the participant has one of the following conditions, colchicine will be temporarily stopped. When the condition of the participant improves, colchicine will be given again after the judgment from the doctor of the research team. For participants unable to receive colchicine again, they will receive regular follow-up only.
1. . There are life-threatening hemorrhage including gastrointestinal hemorrhage and hemorrhage from other vital organs such as lungs or brain.
2. . There are life-threatening bacterial, fungal or viral infection (not included hepatitis B and C virus).
3. . Patient has serum creatinine level \> 1.5 mg/dL.
4. . Patient has white blood cell count \< 1500/µL, platelet count \< 30000/µL or hemoglobin \< 9.0 gm/dL after medication.
5. . The research team decides that the participant is not suitable to continue the study caused by abnormality of any vital organ or severe side effects caused by the study.
4. Colchicine will be temporarily stopped before non-curative operative resection of tumor or transcatheter arterial chemoembolization until participant has body temperature \< 38 ℃, same hepatic reserved function as before, and serum creatinine level \< 1.5 mg/dL.
5. no need to stop colchicine during irradiation therapy, pure ethanol injection or local radiofrequency abrasion
6. Colchicine needs to be temporarily reduced to half of the original dose when the participant will temporarily take P-Glycoprotein inhibitor or strong Cytochrome P450 3A4 inhibitor.
The conditions for the participant to withdraw or terminate the trial:
1. Participant suffers from systemic itching, nausea, vomiting, abdominal pain, fever, or skin rash after colchicine administration.
2. Participant is unable to tolerate 1.5 mg total daily dose of colchicine for at least 4 cycles. This does not include temporarily reduce dose to total 1 mg during temporarily application of P-Glycoprotein inhibitor or strong Cytochrome P450 3A4 inhibitor.
Follow-up procedures and items for the participants to co-operate:
All participants will be followed according to the guide line of the National Health Council and the clinical practice in the treatment of hepatic malignancy. Ultrasonography, contrasted-enhanced computed tomography or magnetic resonance imaging will be performed within every 3 to 4 months. Chest x-ray and whole body bone scan will be followed based on the condition of the participants. Serum alpha-fetoprotein or CA19-9 will be determined within 3 months in participants with abnormal original levels. The complete blood count, hepatic and renal function will be determined at least one session every month. The participants are asked to visit investigators' outpatient clinic at least one session every month.
Concomitant treatment:
1. Permitted:
non-curative operative resection of the tumor, local abrasion therapy, local irradiation therapy, transcatheter arterial chemoembolization, target therapy, immunotherapy
2. Prohibited:
systemic chemotherapy, other clinical trial testing drugs, Chinese traditional medicine, herb drugs
Statistical analysis
1.Statistical Method for Efficacy / Safety measurements: (A) Survival analysis for efficacy: (log-rank test and median survival)
* colchicine combined with other therapy is better than other therapy without target drug or immunotherapy
* colchicine combined with other therapy is not inferior than target drug or immunotherapy combined with other therapy (B) Safety measurements The safety assessment is presented in a narrative statistical manner for the collection of participants' severe adverse events and adverse events.
1. Written informed consent before study specific procedures are undertaken. The investigators will explain the contents of the trial especially the information about the possible side effects, other alternative treatment and the right to withdraw based on the participant own willing to the candidates. Patient can choose to sign or not to sign the inform consent based on his/her own decision after completely understanding the investigators explanation.
2. The process of the experiment
Start to receive colchicine:
Participant will start to receive colchicine starting from 2 tablets after meal twice per day (total 2 mg).
Adjustment the dosage of colchicine during study: based on the following steps:
2 tablets-2 tablets-2 tablets (three times per day, after meal, total 3 mg, maximum dose)\<-\> 2 tablets -1 tablet -2 tablets (three times per day, after meal, total 2.5 mg)\<-\>2 tablets -2 tablets (twice per day, after meal, 2 mg, starting dose)\<-\>1 tablet -1 tablet -1 tablet (three times per day, after meal, 1.5 mg, minimum dose)
1. The colchicine dosage will be changed when the hepatic reserved function of the participant changes to Child score 8-9 points according to the following rules.
1. 1 tablet after meal three times per day with total dose of 1.5 mg; continue 4 days and stop for 3 days (1 cycle)
2. If the hepatic reserved function of the participant returns to Child score \< 8 points, the dosage changes to starting dose.
3. If the hepatic reserved function of the participant changes to Child score \> 9 points, colchicine will be stopped and participant receives regular follow-up only.
2. If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again according to the above steps of dose adjustment.
3. If the participant has one of the following conditions, colchicine will be temporarily stopped. When the condition of the participant improves, colchicine will be given again after the judgment from the doctor of the research team. For participants unable to receive colchicine again, they will receive regular follow-up only.
1. . There are life-threatening hemorrhage including gastrointestinal hemorrhage and hemorrhage from other vital organs such as lungs or brain.
2. . There are life-threatening bacterial, fungal or viral infection (not included hepatitis B and C virus).
3. . Patient has serum creatinine level \> 1.5 mg/dL.
4. . Patient has white blood cell count \< 1500/µL, platelet count \< 30000/µL or hemoglobin \< 9.0 gm/dL after medication.
5. . The research team decides that the participant is not suitable to continue the study caused by abnormality of any vital organ or severe side effects caused by the study.
4. Colchicine will be temporarily stopped before non-curative operative resection of tumor or transcatheter arterial chemoembolization until participant has body temperature \< 38 ℃, same hepatic reserved function as before, and serum creatinine level \< 1.5 mg/dL.
5. no need to stop colchicine during irradiation therapy, pure ethanol injection or local radiofrequency abrasion
6. Colchicine needs to be temporarily reduced to half of the original dose when the participant will temporarily take P-Glycoprotein inhibitor or strong Cytochrome P450 3A4 inhibitor.
The conditions for the participant to withdraw or terminate the trial:
1. Participant suffers from systemic itching, nausea, vomiting, abdominal pain, fever, or skin rash after colchicine administration.
2. Participant is unable to tolerate 1.5 mg total daily dose of colchicine for at least 4 cycles. This does not include temporarily reduce dose to total 1 mg during temporarily application of P-Glycoprotein inhibitor or strong Cytochrome P450 3A4 inhibitor.
Follow-up procedures and items for the participants to co-operate:
All participants will be followed according to the guide line of the National Health Council and the clinical practice in the treatment of hepatic malignancy. Ultrasonography, contrasted-enhanced computed tomography or magnetic resonance imaging will be performed within every 3 to 4 months. Chest x-ray and whole body bone scan will be followed based on the condition of the participants. Serum alpha-fetoprotein or CA19-9 will be determined within 3 months in participants with abnormal original levels. The complete blood count, hepatic and renal function will be determined at least one session every month. The participants are asked to visit investigators' outpatient clinic at least one session every month.
Concomitant treatment:
1. Permitted:
non-curative operative resection of the tumor, local abrasion therapy, local irradiation therapy, transcatheter arterial chemoembolization, target therapy, immunotherapy
2. Prohibited:
systemic chemotherapy, other clinical trial testing drugs, Chinese traditional medicine, herb drugs
Statistical analysis
1.Statistical Method for Efficacy / Safety measurements: (A) Survival analysis for efficacy: (log-rank test and median survival)
* colchicine combined with other therapy is better than other therapy without target drug or immunotherapy
* colchicine combined with other therapy is not inferior than target drug or immunotherapy combined with other therapy (B) Safety measurements The safety assessment is presented in a narrative statistical manner for the collection of participants' severe adverse events and adverse events.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hepatocellular Carcinoma Stage IIIB
Cholangiocarcinoma, Intrahepatic
Cholangiocarcinoma; With Hepatocellular Carcinoma
Hepatocellular Carcinoma Stage IV
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
open labeled
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
colchicine group
The participants will receive colchicine starting from 2 tablets after meal twice per day (total 2 mg). The dose will be adjusted ranging from total minimum 1.5 mg to maximum 3 mg per day based on the condition and tolerance of the participant. One cycle of treatment is defined as 4 days treatment and 3 days off. The participants will receive repeated cycles till the participants quit the trial.
Group Type
EXPERIMENTAL
Colchicine Tablets
Intervention Type
DRUG
three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Colchicine Tablets
three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
(A). Primary hepatic malignancy including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, hepatocellular-cholangiocarcinoma, poorly differentiated or undifferentiated primary hepatic malignancy.
1. Diagnosis of hepatocellular carcinoma: Patient has at least one of the following criteria: (1) positive for hepatocellular carcinoma evidenced by cytology or pathology, (2) serum alpha-fetoprotein level \> 400 ng/mL and has evidence of hepatocellular carcinoma on contrast-enhanced computed tomography or magnetic resonance imaging.
2. Diagnosis of intrahepatic cholangiocarcinoma: Patient has at least one of the following criteria: (1) evidenced by cytology or pathology, (2) serum CA19-9 level \> 10 times of normal upper limit and has evidence on contrast-enhanced computed tomography or magnetic resonance imaging, and no evidence of extrahepatic original malignancy.
3. Diagnosis of hepatocellular-cholangiocarcinoma: concomitantly fit at least one of the items described in (a) and (b)
4. Diagnosis of poorly differentiated or undifferentiated primary hepatic malignancy: Patient fits all of the following criteria: (1) evidenced of malignancy other than hepatocellular carcinoma, intrahepatic cholangiocarcinoma or hepatocellular-cholangiocarcinoma by cytology or pathology, (2) no evidence of extrahepatic original malignancy
(B). Primary hepatic malignant tumors unable to receive curative treatment indicate that the malignancy can not be completely eliminated by operative resection, liver transplantation or local abrasion therapy. Patient also needs to fit at least one of the following criteria: (1) evidence of distant metastasis or large vessels (intrahepatic first branch portal vein, portal main trunk, major hepatic vein or inferior vena cava) invasion, (2) unable to be controlled by transcatheter arterial chemoembolization including appearance of new rather than incompletely treated nodules within 3 months of chemoembolization, or chemoembolization fails
(C). The performance status of the patient based on the Eastern Cooperative Oncology Group (ECOG) belongs to 0 or 1 and the calculated Child score is below 8 points.
1. Diagnosis of hepatocellular carcinoma: Patient has at least one of the following criteria: (1) positive for hepatocellular carcinoma evidenced by cytology or pathology, (2) serum alpha-fetoprotein level \> 400 ng/mL and has evidence of hepatocellular carcinoma on contrast-enhanced computed tomography or magnetic resonance imaging.
2. Diagnosis of intrahepatic cholangiocarcinoma: Patient has at least one of the following criteria: (1) evidenced by cytology or pathology, (2) serum CA19-9 level \> 10 times of normal upper limit and has evidence on contrast-enhanced computed tomography or magnetic resonance imaging, and no evidence of extrahepatic original malignancy.
3. Diagnosis of hepatocellular-cholangiocarcinoma: concomitantly fit at least one of the items described in (a) and (b)
4. Diagnosis of poorly differentiated or undifferentiated primary hepatic malignancy: Patient fits all of the following criteria: (1) evidenced of malignancy other than hepatocellular carcinoma, intrahepatic cholangiocarcinoma or hepatocellular-cholangiocarcinoma by cytology or pathology, (2) no evidence of extrahepatic original malignancy
(B). Primary hepatic malignant tumors unable to receive curative treatment indicate that the malignancy can not be completely eliminated by operative resection, liver transplantation or local abrasion therapy. Patient also needs to fit at least one of the following criteria: (1) evidence of distant metastasis or large vessels (intrahepatic first branch portal vein, portal main trunk, major hepatic vein or inferior vena cava) invasion, (2) unable to be controlled by transcatheter arterial chemoembolization including appearance of new rather than incompletely treated nodules within 3 months of chemoembolization, or chemoembolization fails
(C). The performance status of the patient based on the Eastern Cooperative Oncology Group (ECOG) belongs to 0 or 1 and the calculated Child score is below 8 points.
Exclusion Criteria
1. . life-threatening hemorrhage at the present time
2. . life-threatening bacterial, fungal or viral infection (not included hepatitis B and C virus) at the present time
3. . extrahepatic original malignancy unable to be controlled
4. . serum creatinine level \> 1.5 mg/dL.
5. . Patient must receive long-term statin or fibrates drugs. The doses of these medications can not be altered.
6. . Patient has white blood cell count \< 1500/µL, platelet count \< 30000/µL or hemoglobin \< 9.0 gm/dL after medication.
7. . Pregnant woman or plan to be a pregnant woman
8. . allergy to colchicine or has history of severe side effects caused by colchicine
9. . Patient has received systemic chemotherapy within 2 months before enrollment or plans to receive systemic chemotherapy in the future.
10. . Patient is under or plans to receive other clinical trial testing drug.
11. . Patient has severe malfunction of vital organs and can not participate in this study justified by the member of the research team.
12. . Patient is under or plans to receive Chinese traditional medicine or herb drugs.
13. . Patient is under or plans to receive hospice care.
14. . Patient took other clinical trial testing drug within 3 months before enrollment.
15. . Patient can not quit drug abuse or heavy alcohol drinking.
2. . life-threatening bacterial, fungal or viral infection (not included hepatitis B and C virus) at the present time
3. . extrahepatic original malignancy unable to be controlled
4. . serum creatinine level \> 1.5 mg/dL.
5. . Patient must receive long-term statin or fibrates drugs. The doses of these medications can not be altered.
6. . Patient has white blood cell count \< 1500/µL, platelet count \< 30000/µL or hemoglobin \< 9.0 gm/dL after medication.
7. . Pregnant woman or plan to be a pregnant woman
8. . allergy to colchicine or has history of severe side effects caused by colchicine
9. . Patient has received systemic chemotherapy within 2 months before enrollment or plans to receive systemic chemotherapy in the future.
10. . Patient is under or plans to receive other clinical trial testing drug.
11. . Patient has severe malfunction of vital organs and can not participate in this study justified by the member of the research team.
12. . Patient is under or plans to receive Chinese traditional medicine or herb drugs.
13. . Patient is under or plans to receive hospice care.
14. . Patient took other clinical trial testing drug within 3 months before enrollment.
15. . Patient can not quit drug abuse or heavy alcohol drinking.
Minimum Eligible Age
20 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kaohsiung Medical University
OTHER
Sponsor Role
collaborator
Kaohsiung Medical University Chung-Ho Memorial Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zu-Yau Lin
professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zu Y Lin, MD
Role: PRINCIPAL_INVESTIGATOR
Kaohsiung Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaohsiung Medical University Hospital
Kaohsiung City, , Taiwan
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Taiwan
References
Explore related publications, articles, or registry entries linked to this study.
Arrieta O, Rodriguez-Diaz JL, Rosas-Camargo V, Morales-Espinosa D, Ponce de Leon S, Kershenobich D, Leon-Rodriguez E. Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis. Cancer. 2006 Oct 15;107(8):1852-8. doi: 10.1002/cncr.22198.
Reference Type
BACKGROUND
Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010 Jun;48(5):407-14. doi: 10.3109/15563650.2010.495348.
Reference Type
BACKGROUND
Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, Moratti M, Gaschino G, Giammaria M, Ghisio A, Belli R, Trinchero R. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005 Sep 27;112(13):2012-6. doi: 10.1161/CIRCULATIONAHA.105.542738.
Reference Type
BACKGROUND
Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U, Schaefer C, Stojanov S, Timmann C, Keitzer R, Ozdogan H, Ozen S. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007 Feb;119(2):e474-83. doi: 10.1542/peds.2006-1434. Epub 2007 Jan 22.
Reference Type
BACKGROUND
Leighton JA, Bay MK, Maldonado AL, Schenker S, Speeg KV. Colchicine clearance is impaired in alcoholic cirrhosis. Hepatology. 1991 Dec;14(6):1013-5.
Reference Type
BACKGROUND
Rochdi M, Sabouraud A, Girre C, Venet R, Scherrmann JM. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol. 1994;46(4):351-4. doi: 10.1007/BF00194404.
Reference Type
BACKGROUND
Ferron GM, Rochdi M, Jusko WJ, Scherrmann JM. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J Clin Pharmacol. 1996 Oct;36(10):874-83. doi: 10.1002/j.1552-4604.1996.tb04753.x.
Reference Type
BACKGROUND
Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010 Apr;62(4):1060-8. doi: 10.1002/art.27327.
Reference Type
BACKGROUND
Lin ZY, Wu CC, Chuang YH, Chuang WL. Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci. 2013 Sep 3;93(8):323-8. doi: 10.1016/j.lfs.2013.07.002. Epub 2013 Jul 16.
Reference Type
BACKGROUND
Wu CC, Lin ZY, Kuoc CH, Chuang WL. Clinically acceptable colchicine concentrations have potential for the palliative treatment of human cholangiocarcinoma. Kaohsiung J Med Sci. 2015 May;31(5):229-34. doi: 10.1016/j.kjms.2015.01.008. Epub 2015 Mar 10.
Reference Type
BACKGROUND
Lin ZY, Kuo CH, Wu DC, Chuang WL. Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines. Kaohsiung J Med Sci. 2016 Feb;32(2):68-73. doi: 10.1016/j.kjms.2015.12.006. Epub 2016 Feb 2.
Reference Type
BACKGROUND
Lin ZY, Yeh ML, Liang PC, Chen SC, Huang CF, Huang JF, Dai CY, Yu ML, Chuang WL. Phase IIb Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine. Kaohsiung J Med Sci. 2025 Sep 27:e70121. doi: 10.1002/kjm2.70121. Online ahead of print.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KMUHIRB-F(II)-20190152
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
NCT04135690
UNKNOWN
PHASE2
Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients
NCT02813096
UNKNOWN
NA
Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
NCT02585479
WITHDRAWN
PHASE2/PHASE3
Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma
NCT02773485
UNKNOWN
PHASE3
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
NCT04962958
UNKNOWN
PHASE2
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
NCT01042041
COMPLETED
PHASE1
Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus
NCT04069949
UNKNOWN
PHASE1/PHASE2
Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma
NCT02425605
COMPLETED
PHASE2
Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma
NCT06417606
NOT_YET_RECRUITING
PHASE4
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
NCT06903273
NOT_YET_RECRUITING
PHASE2
Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients
NCT00644020
UNKNOWN
NGS as the First-line Treatment in Advanced Biliary Tract Cancer
NCT04172402
COMPLETED
PHASE2
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
NCT03510871
COMPLETED
PHASE2
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
NCT04170179
UNKNOWN
PHASE2
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
NCT01033240
COMPLETED
PHASE2
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT01004978
COMPLETED
PHASE3
Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma
NCT06632717
RECRUITING
PHASE2
Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
NCT05065957
RECRUITING
PHASE2/PHASE3
Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
NCT01409499
COMPLETED
PHASE4
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
NCT06505486
RECRUITING
Alectinib in Combination with Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided with Serum RNase1 and Tumor Expression of PD-L1
NCT06354387
ACTIVE_NOT_RECRUITING
PHASE1
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
NCT04256980
COMPLETED
PHASE2
Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma
NCT01097083
TERMINATED
PHASE2
A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
NCT01997957
UNKNOWN
PHASE4
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
NCT04618367
COMPLETED
NA